Preliminary results of a phase I/II study of weekly or twice weekly bortezomib in combination with rituximab, in patients with follicular lymphoma, mantle cell lymphoma and Waldenström's macroglobulinaemia
Agathocleous, A., Rule, S., Johnson, P., Radford, J.A., Lafon, N., Hunter, H., Kerr, J.P., Neeson, S.M., Matthews, J., Strauss, S., Montoto, S., Rohatiner, A.Z.S. and Lister, T.A. (2007) Preliminary results of a phase I/II study of weekly or twice weekly bortezomib in combination with rituximab, in patients with follicular lymphoma, mantle cell lymphoma and Waldenström's macroglobulinaemia. Blood, 110, (11), p.754A.
Download
Full text not available from this repository.
Description/Abstract
Introduction: Rituximab (R) is an integral component of therapy for B-cell lymphoid malignancies; bortezomib (Btz) has shown provocative single agent activity in Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL) and Waldenström’s Macroglobulinaemia (WM), providing the rationale for investigating the combination.
Patients+Methods: Forty-five adult patients (pts.) (30 men, 15 women) with histologically confirmed recurrent CD20+ve FL, MCL or WM, median age 60 years (range 45-79), FL: 17, MCL: 18, WM: 10, stage III/IV 40 (93%), bone marrow (BM) infiltration 32 (73%), elevated LDH 22 (49%), performance status 1 22 (49%), were enrolled in a randomised trial comparing 2 schedules of Brz+R: Arm A (twice weekly) Btz: 1.3mg/m2 (on days 1, 4, 8, 11 of a 21-day cycle) and R: 375mg/m2 (on day 1) for 8 cycles, or Arm B (weekly) Btz: 1.6mg/m2 (on days 1, 8, 15, 22 of a 35-day cycle) and R: 375mg/m2 (on days 1, 8, 15, 22 of cycles 1 and 4) for 6 cycles (23 arm A, 22 arm B). The median number of previous treatments was 2 (range 1-7). Seventeen pts. had received a R-containing regimen, with response lasting >6 months, and 8 high-dose treatment. Response was evaluated using the IWR criteria (Cheson et al, JCO17: 1244, 1999) and the updated response criteria from the 3rd International Workshop on WM (Treon et al, Blood107: 3442, 2006)
Results: Ability to deliver the therapy, toxicity and efficacy were equivalent in both arms. The median number of cycles given in arm A was 4 and 5 in arm B. Haematological toxicity (grade3: anaemia 0%, neutropenia 25%, thrombocytopenia 22%) was significantly influenced by the high percentage of pts. with BM infiltration and concomitant cytopenia on entry to the trial. The most common non-haematological adverse events were fatigue (76%), nausea (56%), diarrhoea (56%), lethargy (46%). Neurotoxicity occurred in 19 pts. (46%) (10 pts. grade 1, 7 pts. grade 2, 2 pts. grade 3). Btz dose was reduced in 7 pts.; 5 doses were omitted because of neuro or haematological toxicity. In 16 pts., treatment was delayed by 1-14 days and in 24 pts. treatment was stopped prematurely. The reasons for stopping treatment were: treatment-related toxicity 11 pts., progressive disease 9 pts., patient’s preference 3 pts., myocardial infarction 1 pt. One pt. was excluded having been found ineligible post randomisation. Thirty-nine pts. (21 arm A, 18 arm B) are evaluable for response so far, one having only received 1 cycle of therapy, which had to be discontinued because of excessive toxicity. 15/32 were in remission (CR, CRu, PR) at the completion of therapy, 7/7 at "mid-therapy" assessment, and 5 have yet to be evaluated. Thus the overall response rate (RR) presently is 22/39 (56%) (CR, CRu, PR), FL 44%, MCL 46%, WM 90%.
Conclusions:
The combination was active in pts. with recurrent NHL especially WM (RR 90%), despite multiple previous treatments,
The weekly schedule is preferable being more convenient, as efficacious and no more toxic.
Further investigation is warranted, despite not insignificant therapy compromising toxicity.
| Item Type: | Article |
|---|---|
| Additional Information: | ASH Annual Meeting Abstracts, Poster Session: Lymphoma: Therapy with Biologic Agents excluding Pre-Clinical Models. Abstract 2559. |
| ISSNs: | 0006-4971 (print) |
| Related URLs: | |
| Keywords: | rituximab, patient, combination, lymphoma, cell, time, cell lymphoma |
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) Q Science > QH Natural history > QH426 Genetics |
| Divisions: | University Structure - Pre August 2011 > School of Medicine > Cancer Sciences |
| Item ID: | 62665 |
| Date Deposited: | 11 Nov 2008 |
| Last Modified: | 02 Mar 2012 12:52 |
| Contributors: | Agathocleous, A. (Author) Rule, S. (Author) Johnson, P. (Author) Radford, J.A. (Author) Lafon, N. (Author) Hunter, H. (Author) Kerr, J.P. (Author) Neeson, S.M. (Author) Matthews, J. (Author) Strauss, S. (Author) Montoto, S. (Author) Rohatiner, A.Z.S. (Author) Lister, T.A. (Author) |
| Date: | 16 November 2007 |
| Additional Information: | ASH Annual Meeting Abstracts, Poster Session: Lymphoma: Therapy with Biologic Agents excluding Pre-Clinical Models. Abstract 2559. |
| Status: | Published |
| URI: | http://eprints.soton.ac.uk/id/eprint/62665 |
Actions (login required)
 |
View Item |
